Chemed Corp: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Jul 29, 2022 and accepted by EDGAR at Jul 29, 2022, 10:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $297.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $597.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-04-01 to 2022-06-30 | $336.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2022-01-01 to 2022-06-30 | $673.4m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2022-04-01 to 2022-06-30 | $87.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-01-01 to 2022-06-30 | $177.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | $91.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | $181.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-04-01 to 2022-06-30 | $902.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2022-01-01 to 2022-06-30 | $1.7m | us-gaap:InterestExpense |
| Income tax | 3 months2022-04-01 to 2022-06-30 | $19.6m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | $40.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-04-01 to 2022-06-30 | $66.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | $130.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | $4.40 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | $8.62 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | $4.45 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | $8.73 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 15,111,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 15,152,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | $157.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $25.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2022-01-01 to 2022-06-30 | $10.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months2022-01-01 to 2022-06-30 | $77.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-06-30 | $9.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $203.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $1.31bn | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $285.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $628.0m | us-gaap:Liabilities |
| Long-term debt | At period end2022-06-30 | $111.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-06-30 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2022-06-30 | $685.0m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2022-06-30 | 14,904,946 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001562762-22-000308. Last ingested by Listed: Oct 29, 2026, 09:14 ET. Listed shows no prices and gives no investment advice.